Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
NCT ID: NCT01308437
Last Updated: 2023-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
134 participants
INTERVENTIONAL
2011-03-31
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There are two phases of the study, which are as follows:
1. Phase 1 is a comparative phase in which there will be 2 arms (which are described in the section below).
2. Phase 2 is a follow up phase only applicable to Wosulin Arm.
The study will last for 54 weeks for the patients enrolled in Wosulin arm and approximately 28 weeks for the patients enrolled in the comparator arm.
Two hundred and forty two patients will be enrolled considering an estimated dropout rate of 15% for a sample size of approximately 105 evaluable patients per arm. The total planned enrollment period for this study is approximately 3 months (90 days).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes
NCT06685185
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
NCT04848480
A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus
NCT04161976
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)
NCT01275131
A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
NCT02623478
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Wosulin (N or 70/30 with R)
Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
Wosulin (N or 70/30 with R)
Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
Novolin® (N or 70/30 with R)
Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
Novolin® (N or 70/30 with R)
Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Wosulin (N or 70/30 with R)
Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
Novolin® (N or 70/30 with R)
Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects who have been pre-diagnosed as cases of type-1 diabetes (fasting C-peptide \< 0.5 nmol/L) and have been on an insulin regimen for at least 12 months prior to inclusion in the trial.
3. Subjects who have been on a stable regimen of recombinant human insulin or analogs for at least 3 months prior to randomization. (A stable regimen is defined as the dose within +/- 10%).
4. Male or female subjects ≥ 18 and \< 55 years of age.
5. Subjects with body mass index (BMI) of ≥18.0 to \< 35.0 kg/m2
6. Subjects with glycosylated hemoglobin (HbA1c) levels between ≥6.5 and \< 9.5%
7. Subjects who are cooperative, reliable, and agree to have regular injections of insulin and are willing to comply with protocol procedures.
8. Female subjects who are not pregnant and non-lactating with adequate protection from conception and fulfilling one of the following criteria are also eligible if within ≥ 18 and \< 55 years age limits:
1. Women of childbearing potential on an acceptable method of birth control (including but not limited to barrier-method, contraceptives, or intrauterine device)
2. Women with history of bilateral tubal ligation,
3. Women who have undergone total hysterectomy
4. Women who are two years post-menopausal
9. Subjects who are able to use the self glucose-monitoring device and to self inject insulin.
Exclusion Criteria
2. Compromised hepatic or renal function, as shown by but not limited to:
i.Baseline AST or ALT \>3 times the upper limit of normal range, and/or ii.Serum Creatinine \>2.0 mg/dl and/or iii.BUN \>30 mg/dl Abnormal laboratory findings will be discussed with the medical monitor prior to the subject's entry.
3. Employee of Investigator or have direct involvement with trial or other trials under the direction of Investigator.
4. Those treated with other investigational agents or devices within previous 30 days, from screening, have planned use of an investigational drug or device, or have been previously randomized in this trial.
5. History or evidence of allergy to insulin preparations.
6. History or evidence of severe hypoglycemia (severe hypoglycemic episode defined as the subject required glucose, glucagon, orange juice etc administered by a second person)
7. Requirement for total daily dose of insulin is \>1.4 units/kg
8. Who have received Wockhardt's (Wosulin) or Novo Nordisk's Insulin (Novolin® R, Novolin® N, Novolin® 70/30, in US and Actrapid® Insulatard®, and Mixtard® in India) during the previous one year.
9. Serum AIA level \> 20 microU/ml.
10. Receipt of any insulin of an animal origin during the last 3 years.
11. Currently receiving or have received within the last year any immunomodulators medications, including corticosteroids that would possibly modify antibody generation either at the enrollment or during the course of the study. (Topical/ ophthalmic/intra-articular/nasal spray corticosteroids will be allowed).
12. Hepatitis B or Hepatitis C or HIV positive.
13. Oral hypoglycaemic agent within 4 weeks prior to signing the consent form.
14. Who have undergone pancreatectomy or pancreas/islet cell transplant.
15. Unlikely to comply with the study protocol e.g. unable to return periodically for subsequent visits.
16. History or evidence of active severe proliferative retinopathy, nephropathy and/or neuropathy significant cardiovascular disease, anemia or hemoglobinopathy, uncontrolled hypothyroidism or uncontrolled hyperthyroidism, alcohol or drug abuse or any other medical condition that in the opinion of Investigator can interfere with the study.
17. Judged by the investigator as inappropriate to participate in the study for any reason other than those mentioned above.
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wockhardt
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ashima Bhatia, M.D.
Role: STUDY_DIRECTOR
Wockhardt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Clinical Investigators, Inc. dba Diabetes Research Center
Tustin, California, United States
International Research Associates
Hialeah, Florida, United States
The Center for Diabetes and Endocrine Care
Hollywood, Florida, United States
Baptist Diabetes Associates, PA
Miami, Florida, United States
Suncoast Clinical Research
New Port Richey, Florida, United States
Ormond Medical Arts Pharmaceutical Research Center
Ormond Beach, Florida, United States
Suncoast Clinical Research
Palm Harbor, Florida, United States
International Clinical Research - US, LLC
Sanford, Florida, United States
Cotton-O'Neil Clinical Research Center, Diabetes & Endocrinology
Topeka, Kansas, United States
Kentucky Diabetes Endocrinology Center
Lexington, Kentucky, United States
Endocrine & Metabolic Consultants
Rockville, Maryland, United States
ActivMed Practices and Research
Haverhill, Massachusetts, United States
Alzohaili Medical Consultants
Dearborn, Michigan, United States
ActivMed Practices and Research
Rochester, New Hampshire, United States
University Diabetes & Endocrine Association
Chattanooga, Tennessee, United States
Sergio Rovner, MD
El Paso, Texas, United States
Optimum Clinical Research, Inc.
Salt Lake City, Utah, United States
Dr Rakesh Sahay
Hyderabad, Andhra Pradesh, India
Dia Care - A Complete Diabetes Care Centre
Ahmedabad, Gujarat, India
Dr Sanjay Kalra
Karnāl, Haryana, India
Dr Mala Dharmalingam
Bangalore, Karnataka, India
Bangalore Diabetes Hospital
Bangalore, Karnataka, India
Dr Sharad Pendsey
Nagpur, Maharashtra, India
Diabetes Thyroid &Endocrine Centre
Jaipur, Rajasthan, India
Bhandari's Clinic
Jaipur, Rajasthan, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P3-WOS-IMS-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.